BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
    • Interviews
  • News
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Exosomes
  • CAR-T
  • Cord Blood
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » Anemocyte to expand its plasmid manufacturing capabilities
Anemocyte plasmid manufacturing

Anemocyte to expand its plasmid manufacturing capabilities

September 29, 2019 By Cade Hildreth (CEO) 1 Comment

AnemocyteA new state-of-the-art facility dedicated to plasmid manufacturing is now operational in Gerenzano, Italy. The new site will couple with the existing GMP facility active in the Cell and Gene (C&G) therapy space. With 800m2 (8,000 square feet) of cleanrooms, the two facilities of Anemocyte, the first Biotech Manufacturing Organisation (BMO), will address manufacturing needs of Somatic Cells, Non-Viral Modified Cells, Vesicles and Plasmids for Viral Vectors.

Discover class-defining bioproduction tools.

The new Plasmid Manufacturing Unit will replace the existing one allowing production of R&D, High Quality and GMP plasmids addressing all applications: from discovery research through commercial production.

“Anemocyte’s new facility is built with modular cleanroom areas resulting in a threefold higher manufacturing output when compared with the existing one, maintaining the highest possible standard of quality and compliance” said Marco Ferrari, Anemocyte CEO. “The new facility is part of the Exellula project that will also include a third GMP facility aimed to address industry manufacturing needs up to commercial scale.”

bitbio

Such an increase in Anemocyte capacity and experience combines perfectly with the over sixty years of successful manufacturing stories within the Nine Trees Group strengthening Anemocyte’s unique position as Biotech Manufacturing Organization (BMO) capable to address C&G manufacturing need from discovery clinical research through commercial.

Last February Anemocyte appointed M+W Italy, a leader in pharma/biotech custom engineering and construction, partner for the design and construction of the new plasmid facility.

iPSC-derived cardiomyocte therapy

“M+W Italy is proud to be Anemocyte’s partner for the engineering study and the construction of the new plasmid facility. Our unique expertise will allow Anemocyte to complete the site revamping without any impact on the business continuity ensuring the highest quality standards in the industry” said Ettore Marco Merigioli, M+W Italy Managing Director.

Pluristyx

Since the beginning of the project, M+W Italy have supported Anemocyte in the definition of process requirements for new areas development, selecting the best available engineering solutions. Subsequently M+W Italy is driving the new facility construction activities.

EXELLULA Project

EXELLULA project is the first Italian industrial complex entirely dedicated to the development and production of Advanced Therapy Medicinal Products (ATMP) for third parties, and a world centre of excellence for nonviral technologies.

It is an all-Italian investment aimed at creating the most important national manufacturing centre for Cell and Gene Therapies (CGT), one of the most significant private investments in the sector of contract manufacturing of cell and gene therapies currently underway in Europe, with over 2000 square metres of GMP and GMP-compliant facilities for the development and production of Advanced Therapy Medicinal Products (ATMP) and over 500 square metres dedicated to their research and innovation.

Do you have questions about Anemocyte? Ask them in the comments below.

4.9/5 - (11 votes)

Filed Under: Cell Therapy, Stem Cell News Tagged With: Anemocyte

Related

About Cade Hildreth (CEO)

Cade Hildreth is the Founder of BioInformant.com, the world's largest publisher of stem cell industry news. Cade is a media expert on stem cells, recently interviewed by the Wall Street Journal, Los Angeles Business Journal, Xconomy, and Vogue Magazine. 

Comments

  1. Kawalpreet K Aneja says

    July 17, 2019 at 10:33 am

    Does Anemocyte has any labs near Philadelphia?

    Reply

Tell Us What You Think! Cancel reply

Nanocellect

Marathon Products

Let’s Get Social

  • Facebook
  • Twitter
  • LinkedIn
  • Pinterest
  • Instagram
Menu
  • Blog
  • Stem Cell News
    • Press Releases
  • Stem Cells
    • HSCs
    • iPS Cells
    • MSCs
    • Neural Stem Cells
    • Adipose SCs
  • Exosomes
  • Cell Therapy
    • CAR-T
  • Cord Blood
  • Interviews

Cart

Featured Posts

PolarityTE RMAT

PolarityTE Announces FDA RMAT Awarded to Its Designation Granted to SkinTE®

Advanced Therapy | What is a RMAT Designation (and Who Has One)?

What Is An RMAT? List of Publicly Announced RMAT Designations (64)

i-peaces-cell-manufacturing

I Peace accelerates allogeneic iPSC-derived cell therapies with a high throughput method to identify a large number of donors with specific HLA haplotypes

My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2022 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: Info@BioInformant.com | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.